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Abstract
The prostate is a site of high expression of serine pro-
teinases including members of the kallikrein-related
peptidase (KLK) family, as well as other secreted and
membrane-anchored serine proteinases. It has been
known for some time that members of this enzyme family
elicit cellular responses by acting directly on cells. More
recently, it has been recognised that for serine protein-
ases with specificity for cleavage after arginine and lysine
residues (trypsin-like or tryptic enzymes) these cellular
responses are often mediated by cleavage of members
of the proteinase-activated receptor (PAR) family – a four
member sub-family of G protein-coupled receptors.
Here, we review the expression of PARs in prostate, the
ability of prostatic trypsin-like KLKs and other prostate-
expressed tryptic enzymes to cleave PARs, as well as the
prostate cancer-associated consequences of PAR acti-
vation. In addition, we explore the dysregulation of tryp-
sin-like serine proteinase activity through the loss of
normal inhibitory mechanisms and potential interactions
between these dysregulated enzymes leading to aberrant
PAR activation, intracellular signalling and cancer-pro-
moting cellular changes.
Keywords: cancer; kallikrein-related peptidase;
prostate; proteinase-activated receptor; serine
proteinase.
Introduction
Serine proteinases of the S1A sub-family are characte-
rised by a triad of amino acids consisting of histidine,
aspartate and serine residues in highly conserved
sequence motifs, which are essential for catalytic activity
(Rawlings and Barrett, 1994). These enzymes, which
encompass as many as 140 (Rawlings et al., 2006) of the
total 569 human degradome complement (Lo´pez-Otı´n
and Matrisian, 2007), modulate a variety of cellular pro-
cesses by selective cleavage of specific substrates to
influence cell behaviour (Turk, 2006). Well known physio-
logical examples include the proteinases of the blood
coagulation (e.g., thrombin) (Davie et al., 1991), digestive
(e.g., trypsin) (Yamashina, 1956) and wound healing (e.g.,
plasmin) (Castellino and Ploplis, 2005) cascades. It is
also clear that dysregulated serine proteinase activity
facilitates progression of various diseases including can-
cer (Dano et al., 2005; Turk, 2006; Szabo and Bugge,
2008). The cleavage site specificity of these enzymes is
indicated by the residue six amino acids before the cat-
alytic serine. In the active conformation of the proteinase,
this residue is located at the bottom of a pocket in which
the side-chain of the scissile bond of the substrate is
inserted. An aspartate or, rarely, a glutamate at this site
indicates that the serine proteinase will preferentially
cleave after substrate arginine or lysine residues (trypsin-
like or tryptic substrate specificity); a small hydrophobic
residue in this position specifies preferential cleavage
after large hydrophobic amino acids (chymotrypsin-like
substrate specificity); and larger, usually non-polar resi-
dues at this site specify preferential proteolysis following
small hydrophobic amino acids (elastase-like substrate
specificity) (Perona and Craik, 1995, 1997).
The largest contiguous collection of S1A serine pro-
teinase encoding genes is located within the kallikrein-
related peptidase (KLK) locus at chromosome
19q13.3–13.4 (Gan et al., 2000; Harvey et al., 2000; You-
sef et al., 2000) which consists of 15 genes, 12 of which
encode tryptic serine proteinases: KLK1–2, KLK4–6,
KLK8, KLK10–15 (Borgono and Diamandis, 2004; Cle-
ments et al., 2004). A common site of expression for the
KLKs is the prostate with this tissue a predominant site
of mRNA expression for KLK2, KLK3 (also known as
prostate-specific antigen or PSA), KLK4, KLK11, KLK14
and KLK15 (Clements et al., 2004; Shaw and Diamandis,
2007). In addition, mRNA of KLK6, KLK9, KLK12 and
KLK13 is highly expressed in this tissue, while low or very
low prostatic mRNA expression has been reported for
each of the remaining KLKs (Clements et al., 2004; Shaw
and Diamandis, 2007). In summary, as listed in Table 1
(and described in the references cited therein), tran-
scripts of each KLK are expressed in prostate and all
family members, except KLK8, have been detected at the
protein level in normal or cancerous prostate.
Over the last 15 years, it has been increasingly recog-
nised that many of the cellular effects elicited by trypsin-
like serine proteinases are mediated by activation
of cell surface proteins known as proteinase activated
receptors (PARs). These receptors, which comprise a G
protein coupled receptor sub-family consisting of
PAR1–PAR4, are irreversibly activated by the action of
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proteinases (Vu et al., 1991; Bohm et al., 1996a; Ishihara
et al., 1997; Xu et al., 1998; Boire et al., 2005; Vesey et
al., 2007). In fact, PAR activation is almost exclusively
mediated by serine proteinases with trypsin-like sub-
strate specificity for cleavage following arginine or lysine
residues. As shown in Figure 1A cleavage occurs within
the amino-terminal exodomain of the receptor following
either an arginine or lysine residue generating a new ami-
no-terminal. This neo-epitope serves as a tethered ligand
which binds intramolecularly, causing allosteric changes
within the PAR, followed by receptor coupling to hete-
rotrimeric G proteins and signal transduction (Figure 1B,
activation). Importantly, it is also possible for proteinases
to cleave downstream of the activation site or within a
PAR extracellular loop leading to disarming of the recep-
tor (Oikonomopoulou et al., 2006) (Figure 1B, disarming).
PARs are involved in a number of physiological process-
es, such as cardiovascular responses, neuronal cell sur-
vival, platelet aggregation, inflammation and epidermal
function, and also mediate disease-associated cellular
changes including those necessary for cancer progres-
sion, such as dysregulated cell proliferation and migra-
tion (Macfarlane et al., 2001).
Recently, several prostatic KLKs with trypsin-like sub-
strate specificity have been shown to cleave PARs lead-
ing either to receptor activation or disarming. It is also
known that normal and diseased prostate is the site of
expression of many other tryptic serine proteinases. This
review summarises the current understanding of signal-
ling via PARs in prostate initiated by KLK and other tryp-
tic serine proteinases and highlights the possibility that
as yet untested trypsin-like members of this enzyme
family will also regulate prostatic PAR signalling.
PAR expression in prostate tissue and cell
lines
The mRNA and protein expression patterns of PARs in
prostate, analysed by a number of approaches, are sum-
marised in Table 2. Tissue microarray analysis of a large
number of patient samples indicated elevated PAR1
expression in benign prostatic hyperplasia (BPH) com-
pared to normal prostate stroma (Tantivejkul et al., 2005).
Increased PAR1 expression was also observed in high
grade prostatic intraepithelial neoplasial (PIN) and pros-
tate adenocarcinoma in comparison to normal prostate
stroma, BPH and atrophic prostate tissues (Tantivejkul et
al., 2005). Kaushal and colleagues have also recently
reported correlation of increased PAR1 mRNA and protein
levels with prostate cancer stage. These workers,
employing quantitative PCR analysis of early versus late
stage prostate cancer tissue, showed an increase in
PAR1 mRNA in the late stage cancer samples. Increasing
PAR1 mRNA with prostate cancer stage was similarly
reflected in PAR1 protein expression, as Western blot
analysis of PAR1 protein levels showed a 2.75-fold
increase in late versus early stage disease. This obser-
vation was consistent with their immunohistochemical
analyses that showed low PAR1 expression in 56% (15
of 27) of BPH samples, low to medium expression levels
in 44% (14 of 32) and strong staining in 22% (7 of 32) of
early stage prostate cancer, while strong staining was
656 A.J. Ramsay et al.
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Figure 1 Proteinase-activated receptor cleavage.
(A) Activation sites of the four human PARs. The arrow indicates
the site of proteolytic cleavage necessary for activation and
intracellular signal transduction to occur. (B) Members of the
PAR family of seven transmembrane G protein-coupled recep-
tors are cleaved either at the receptor activation site leading to
signal transduction across the plasma membrane, or down-
stream of the activation site resulting in receptor inactivation
(also known as disarming). Receptor activation involves cleav-
age at an arginine or lysine to expose a tethered ligand which
binds intramolecularly, inducing allosteric changes in the recep-
tor. Receptor disarming involves cleavage distal to the activation
site causing removal of the tethered ligand and inhibition of
receptor activation.
also observed in all 22 advanced prostate cancer tissues.
Interestingly, approximately 50% of the strong staining
seen in early and advanced tumours was in areas
of blood vessels and a weak correlation was found
between levels of PAR1 and the pro-angiogenic factor
vascular endothelial growth factor (VEGF)-2 (Kaushal et
al., 2006).
Similar to PAR1, other members of this receptor family
are also expressed in normal and cancerous prostate. Of
note, in the first paper reporting the cloning of the human
PAR2 cDNA, Nystedt and co-workers demonstrated high
expression of the mRNA for this receptor in normal pros-
tate (Nystedt et al., 1995). Further, Black and co-workers
demonstrated that six matched normal and cancerous
patient samples showed increased mRNA levels of PAR1
(5 of 6), PAR2 (4 of 6) and PAR4 (3 of 6), while PAR3 levels
were consistently low (Black et al., 2007). In addition,
immunohistochemical analysis of 40 patient tissues
showed little PAR1 (7.5%) and PAR2 (13%) in normal
prostate glands, with PAR4 staining apparent in approx-
imately 55% of samples and PAR3 expression completely
absent. PAR expression in prostate cancer samples was
elevated in comparison to normal prostate glands for
PAR1 (45%), PAR2 (42%) and PAR4 (68%), with elevated
expression most notable in cancerous epithelial cells.
Additionally, higher Gleason grade cancers (G7–10) had
increased expression of PAR1 in periglandular stromal
cells compared to lower grade tumours (G5–9), signifying
a shift from epithelial to periglandular expression in pros-
tate cancer progression (Black et al., 2007).
We have also examined the expression of PAR2 in pri-
mary prostate cancer, as well as in bone metastasis. In
these experiments, we used an affinity purified rabbit
anti-PAR2 polyclonal antibody generated against a pep-
tide spanning amino acids 133–146 located in the first
extracellular loop of the receptor (Figure 2A). As shown
in Figure 2B–D, PAR2 is expressed by cells of epithelial
origin with little evidence of stromal staining. PAR2 was
weakly detected in benign glands of BPH (Figure 2B),
more strongly in cells of epithelial origin in cancerous
glands (Figure 2C), as well as strongly in cancer cells in
bone metastases (Figure 2D). A prostate tissue section
incubated without the anti-PAR2 antibody was free of
staining (Figure 2E). These data are consistent with the
observations of Black and co-workers and suggest that
PAR2 expression levels increase during prostate cancer
progression.
Consistent with the prostatic expression of PAR1,
androgen regulation of the encoding gene has been
recently reported (Salah et al., 2005). These workers
showed that stimulation of LNCaP cells with dihydrotes-
tosterone (DHT) increased the transcription of PAR1,
whereas PC-3 cells, which lack an androgen receptor,
were unresponsive. Consistently, PAR1 promoter activity
was increased 3-fold in response to DHT and attributed
to an androgen response element located at -1791 bp to
-1777 bp. Furthermore, consistent with PAR1 androgen
responsiveness, all nine grade- and age-matched neo-
plastic prostate tissue samples before and after andro-
gen ablation therapy displayed a substantial decrease in
PAR1 mRNA levels after androgen ablation. However, as
PAR1 levels are elevated in late, androgen independent
stage disease it is apparent that other mechanisms must
also transcriptionally regulate the encoding gene. Con-
sistent with this proposal, an aggressive, hormone resis-
tant sub-line of LNCaP cells (CL1 cells) generated
through in vitro androgen deprivation, has high levels of
PAR1 mRNA and protein and small amounts of AR pro-
tein; a phenomenon that is also seen in PC-3 cell which
lack androgen receptor (Salah et al., 2005). More recent-
ly, Salah and colleagues employed fluorescence in situ
chromosome hybridisation to indicate that differences in
PAR1 mRNA levels in cell lines of high (CL1 or PC-3) and
low (LNCaP) expression is not due to gene amplification.
These workers also showed that PAR1 mRNA stability is
the same in each of these lines. Importantly, nuclear run-
on assays indicated markedly enhanced PAR1 mRNA
elongation rates in cell lines with high levels of PAR1
mRNA in comparison to cells which have low levels of
this transcript (Salah et al., 2007). These observations
suggest that androgen is involved in regulating PAR1
expression in normal prostate and early stages of pros-
tate cancer, and that an unknown mechanism may reg-
Tryptic serine proteinases and PARs in prostate 657
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Figure 2 Immunohistochemical analysis of PAR2 expression in primary prostate cancer and bone metastasis.
(A) Sequence and location (residues 133–146; extracellular loop 1) of the peptide used to generate a rabbit anti-PAR2 polyclonal
antibody. (B) PAR2 expression in benign glands of benign prostatic hyperplasia. (C) PAR2 expression in cancerous prostate. (D) PAR2
expression in prostate cancer cells in a bone metastasis. (E) Negative control – primary antibody omitted.
ulate its expression in later, hormone resistant disease
stages.
The expression of PARs in prostate derived cell lines
is summarised in Table 3. Both PAR1 and PAR2 are widely
expressed with each analysed cell line expressing these
receptors (Chay et al., 2002; Greenberg et al., 2003; Liu
et al., 2003, 2006; Yin et al., 2003; Wilson et al., 2004;
Myatt and Hill, 2005). In contrast, PAR3 protein has not
been reported to be expressed by any prostate derived
cell line, while PAR4 expression has only been reported
in LNCaP cells (Greenberg et al., 2003). However, reports
from Liu et al. (2003) and Wilson and colleagues (Wilson
et al., 2004) have been inconsistent regarding the pres-
ence of PAR4 mRNA in this cell line.
In summary, it is apparent that PARs are expressed in
both normal and cancerous prostate. The presence of
these receptors and the known roles of PARs as sentinels
of tryptic serine proteinase activity indicate the potential
that these cell surface receptors will be important trans-
ducers of signals initiated by the large number of pro-
static trypsin-like serine proteinases – both KLK and
non-KLK.
PAR cleavage by prostatic trypsin-like
kallikreins
Studies examining the ability of tryptic KLKs and other
trypsin-like serine proteinases to regulate signalling via
PARs are summarised in Table 4. In a significant recent
report Oikonomopoulou and colleagues examined the
ability of three KLK family members (KLK5, KLK6 and
KLK14) to regulate signalling via PAR1, PAR2 and PAR4
(Oikonomopoulou et al., 2006). Mass spectral analysis of
peptides spanning the activation site of each receptor
indicated that a major cleavage site for each KLK is at
the known receptor activation site. In addition, both KLK5
and KLK14 also cleaved upstream of the PAR2 activation
site. Interestingly, only KLK14 was able to cleave at a site
downstream of the activation site of the peptide of one
of the receptors, PAR1 (which would induce disarming of
the receptor in intact cells; Figure 1). Consistent data
were obtained from microscopy analyses of cells stably
expressing rat PAR2. Interestingly, these workers also
showed that KLK5 is less efficient than KLK6 and KLK14
at cleaving at the PAR2 activation site. Furthermore,
experiments analysing Ca2q mobilisation yielded impor-
tant insights on the ability of KLKs to induce differential
signalling in intact cells via PARs. These workers have
proposed that PAR2 is activated by low concentrations
of KLK6, whereas higher enzyme concentration results in
receptor inactivation. Equally as interesting is the pro-
posal that in cells expressing both PAR1 and PAR2, the
former receptor is disarmed by KLK14, whereas the latter
is activated by this enzyme. Adding another layer of com-
plexity, KLK14 was also shown to signal via PAR4, where-
as KLK5 and KLK6 were unable to induce signalling
through this receptor at concentrations that initiated
signalling via PAR2 (Oikonomopoulou et al., 2006). The
observations of Oikonomopoulou and co-workers indi-
cate that individual KLKs can function as both activator
and disarmer of individual PARs, as well as have the abil-
ity to cleave multiple PARs. These findings highlight the
potential complexity of regulation of PAR signalling; par-
ticularly in situations of dysregulated trypsin-like serine
proteinase activity and expression of multiple PARs,
which occur in prostate cancer.
The data of Oikonomopoulou and colleagues have
been partially confirmed by others. Stefansson and co-
workers confirmed the ability of KLK5 and KLK14 to acti-
vate PAR2 by examining calcium mobilisation in cells
stably expressing the human receptor (Stefansson et al.,
2008). This group also examined the ability of the related
enzymes KLK7 (chymotryptic) and KLK8 (tryptic) to sig-
nal via PAR2. Not surprisingly, KLK7 could not signal via
PAR2. Interestingly, however, KLK8 was also unable to
signal through this receptor (Stefansson et al., 2008). In
contrast, whereas Oikonomopoulou and colleagues have
reported that KLK6 cleaves peptides spanning the acti-
vation sites of PAR1, PAR2 and PAR4, Angelo et al. dem-
onstrated that while KLK6 is able to efficiently cleave a
PAR2 activation site spanning peptide, this enzyme is
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Table 3 Summary of studies examining proteinase-activated receptor expression in prostate-derived cell lines.
Prostate cell linea PAR Detection methodb Reference
PNT1A PAR1 mRNA PCR Liu et al., 2003
(prostate epithelium) PAR1 protein FC
No PAR3 mRNA PCR
No PAR4 mRNA PCR
Primary prostate PAR2 protein PAR2 activation Myatt and Hill, 2005
stromal cells (BPH) assay
LNCaP PAR1 mRNA PCR and NB Liu et al., 2003; Chay et al., 2002; Wilson et al., 2004
(prostate cancer lymph PAR2 mRNA PCR Wilson et al., 2004
node metastasis) *PAR3 mRNA
*PAR4 mRNA
*No PAR3 mRNA PCR Liu et al., 2003
*No PAR4 mRNA
PAR1 protein FC and IC Greenberg et al., 2003; Liu et al., 2003; Wilson et al., 2004
PAR2 protein FC and IC Greenberg et al., 2003; Wilson et al., 2004
No PAR3 protein FC Greenberg et al., 2003
PAR4 protein FC
PC-3 PAR1 mRNA PCR and NB Chay et al., 2002; Wilson et al., 2004
(prostate cancer PAR2 mRNA PCR Wilson et al., 2004
bone metastasis) No PAR3 mRNA
No PAR4 mRNA
PAR1 protein IC Chay et al., 2002; Wilson et al., 2004
PAR2 protein IC Wilson et al., 2004
DU145 PAR1 mRNA PCR and NB Chay et al., 2002; Liu et al., 2003, 2006; Wilson et al., 2004
(prostate cancer PAR2 mRNA PCR Wilson et al., 2004
brain metastasis) No PAR3 mRNA PCR Liu et al., 2003; Wilson et al., 2004
No PAR4 mRNA PCR
PAR1 protein FC and IC Chay et al., 2002; Liu et al., 2003, 2006; Wilson et al., 2004
PAR2 protein IC Wilson et al., 2004
Primary prostate PAR2 protein PAR2 activation Myatt and Hill, 2005
stromal cells (BPH) assay
DuCaP versus VCaP PAR1 protein IC Chay et al., 2002
(soft tissue versus (increased in VCaP)
bone met)
AT2.1 versus AT3.1 PAR1 mRNA PCR Yin et al., 2003
(rat prostate carcinoma) (increased in AT3.1)
aCell line designation (origin); BPH, benign prostatic neoplasia.
bFC, flow cytometry; NB, Northern blot; IC, immunocytochemistry.
*Denotes literature conflict.
unable to cleave PAR1 or PAR4 activation site spanning
peptides or a PAR3 peptide (Angelo et al., 2006).
Interestingly, early studies by Molino and co-workers
indicated that KLK1 is unable to cleave PAR1 or PAR2 in
endothelial cells (Molino et al., 1997a) or to cleave a pep-
tide spanning the PAR2 activation site (Molino et al.,
1997b). However, more recently Houle and colleagues
used a rodent paw oedema model to demonstrate that
this proteinase plays a role in inflammation by direct or
indirect activation of PAR4 (Houle et al., 2005).
PAR cleavage by other prostatic trypsin-like
serine proteinases
It is of significance for signalling via PARs that normal
and cancerous prostate and prostate-derived cell lines
express at least 16 other trypsin-like serine proteinases.
These include secreted enzymes, such as trypsin I, II
(Paju et al., 2000; Bjartell et al., 2005) and IV (Takeuchi
et al., 1999; Cottrell et al., 2004); other more complex
secreted serine proteinases, containing modular non-
proteolytic domains, such as factor XIIa (Takeuchi et al.,
1999), plasma kallikrein (Neth et al., 2001; Fink et al.,
2007), urokinase (also known as urinary plasminogen
activator, uPA; Gavrilov et al., 2001; Riddick et al., 2005;
Usher et al., 2005) and protein C (He et al., 1995; Takeu-
chi et al., 1999); the multi-serine proteinase domain con-
taining enzymes polyserase-2 and -3 (Cal et al., 2005,
2006); the glycosyl-phosphatidylinositol membrane-
anchored serine proteinase prostasin (Chen et al., 2001);
as well as nine members of the type II transmembrane
serine proteinase (TTSP) sub-family (Hooper et al., 2001;
Netzel-Arnett et al., 2003) including hepsin, enteropepti-
dase (Cottrell et al., 2004), matriptase/MT-SP1 (Saleem
et al., 2006), TMPRSS2 (Lin et al., 1999), TMPRSS3
(Scott et al., 2001), TMPRSS13 (Kim et al., 2001), human
airway trypsin-like proteinase (HAT) (Hahner et al., 2005),
DESC1 (Lang and Schuller, 2001) and the multi-catalytic
domain TTSP polyserase-1 (Okumura et al., 2006). It is
also interesting to note the co-expression in prostate-
derived cell lines of trypsinogen I, II and IV and the in vivo
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Table 4 Summary of studies examining PAR activation by tryptic KLKs and other trypsin-like serine proteinases.
Serine proteinase Structurea PAR cleavageb Reference
KLK1 Secreted Unable to cleave PAR2 activation peptide sequence Molino et al., 1997a
Unable to activate PAR1 or PAR2 in intact cells Molino et al., 1997b
Activates PAR4 in rodent paw oedema model Houle et al., 2005
KLK5 Secreted Cleaves at activation site of PAR1, PAR2 and PAR4 peptides Oikonomopoulou et al., 2006
Cleaves cell surface hPAR2 and rPAR2 Oikonomopoulou et al., 2006;
Stefansson et al., 2008
Induces Ca2q mobilisation via hPAR2 and rPAR2 Oikonomopoulou et al., 2006;
Stefansson et al., 2008
KLK6 Secreted Cleaves at activation site of PAR1, PAR2 and PAR4 peptides Oikonomopoulou et al., 2006
Cleaves cell surface rPAR2
Induces Ca2q mobilisation via rPAR2
KLK7 Secreted Unable to induce Ca2q mobilisation via hPAR2 Stefansson et al., 2008
KLK8 Secreted Unable to induce Ca2q mobilisation via hPAR2 Stefansson et al., 2008
KLK14 Secreted Cleaves at activation site of PAR1, PAR2 and PAR4 peptides Oikonomopoulou et al., 2006
Cleaves downstream of activation site of PAR1 peptide Oikonomopoulou et al., 2006
Cleaves cell surface hPAR2 and rPAR2 Oikonomopoulou et al., 2006;
Stefansson et al., 2008
Induces Ca2q mobilisation via h/rPAR2 and h/rPAR4 Oikonomopoulou et al., 2006;
Stefansson et al., 2008
Disarms hPAR1 in intact cells Oikonomopoulou et al., 2006
Trypsinogen IV Secreted Induces Ca2q mobilisation via hPAR2 and hPAR4 Cottrell et al., 2004
Cleaves at activation site of PAR1, PAR2 and PAR4 peptides Knecht et al., 2007
Induces Ca2q mobilisation via hPAR1 and hPAR2 Knecht et al., 2007
Causes PAR2 dependent inflammation and hyperalgesia Knecht et al., 2007
HAT TTSP IL-8 release mediated by an anti-PAR2 antibody Iwakiri et al., 2004
inhibitable pathway
Matriptase/MT-SP1 TTSP Induces Ca2q mobilisation via hPAR2 and mPAR2 Takeuchi et al., 2000
Unable to induce Ca2q mobilisation via hPAR1, PAR3 or PAR4
TMPRSS2 TTSP Induces Ca2q mobilisation via hPAR2 Wilson et al., 2005
Unable to induce Ca2q mobilisation via hPAR1
aTTSP, type II transmembrane serine protease.
bh, human; r, rat; m, mouse.
activator of these enzymes, the TTSP enteropeptidase
(Light and Janska, 1989; Kitamoto et al., 1994).
Several of these enzymes have well documented asso-
ciations with cancer progression. For example, the gene
encoding hepsin is one of the most up-regulated genes
in prostate cancer (Dhanasekaran et al., 2001; Luo et al.,
2001b; Magee et al., 2001; Ernst et al., 2002; Halvorsen
et al., 2005), while hepsin protein expression increases
with prostate cancer progression with expression main-
tained in bone metastases (Xuan et al., 2006). Signifi-
cantly, hepsin overexpression in mouse prostate
epithelium caused basement membrane disorganisation,
while overexpression in a mouse model of non-metas-
tasising prostate cancer was accompanied by metastasis
to several organs including liver, bone and lung (Klezo-
vitch et al., 2004).
Similar to hepsin, expression of matriptase/MT-SP1 is
elevated in prostate cancer tissue in comparison to nor-
mal prostate. Significantly, elevated matriptase/MT-SP1
expression is accompanied by a decrease in the expres-
sion of hepatocyte growth factor activator inhibitor-1, the
specific inhibitor of this tryptic proteinase (Saleem et al.,
2006). A role for matriptase/MT-SP1 in prostate cancer
progression has also been indicated by application of the
selective inhibitor, CVS-3983, in a prostate cancer xeno-
graft model. These studies resulted in reduction of both
tumour volume and in vitro cell invasion (Galkin et al.,
2004). Similarly, PC-3 and DU145 cells in which matrip-
tase/MT-SP1 levels had been knocked down, exhibited
reduced growth, invasiveness and migration in vitro and
a reduced ability to grow and develop in vivo (Sanders
et al., 2006).
TMPRSS2, an androgen regulated member of the
TTSP family, is expressed moderately in the glandular
epithelia of normal prostate, PIN and prostate cancer
tissue samples (Lin et al., 1999). Consistently, in situ
hybridisation analysis of patient tissue indicated that
androgen-deprivation therapy was accompanied by sig-
nificantly decreased TMPRSS2 mRNA levels (Vaarala et
al., 2001). Interestingly, although unrelated to its proteo-
lytic activity, fusions of the ETS transcription factor genes
ERG and ETV1 with the promoter of the TTSP gene
TMPRSS2 is a common occurrence in prostate cancer.
These gene fusion events result in the overexpression of
ERG and ETV1 driven by androgen-responsive elements
within the TMPRSS2 promoter. Importantly, TMPRSS2:
ERG fusion prostate cancers have a more aggressive
phenotype, highlighting the potential for this fusion prod-
uct as a discriminating biomarker for advanced prostate
cancer (Tomlins et al., 2005).
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A number of these trypsin-like serine proteinases have
been examined for the ability to signal via PARs (Table
4). These include the membrane anchored tryptic serine
proteinases HAT, matriptase/MT-SP1 and TMPRSS2, as
well as the secreted enzyme trypsin IV. Iwakiri and col-
leagues have proposed that the TTSP HAT induces
release of interleukin-8 (IL-8) via a PAR2-mediated path-
way as inhibition of PAR2 resulted in a decreased HAT-
induced IL-8 release (Iwakiri et al., 2004). Takeuchi and
co-workers have demonstrated that matriptase/MT-SP1
is able to activate human PAR2 and mouse PAR2, but not
human PAR1, PAR3 or PAR4 in receptor expressing
oocytes (Takeuchi et al., 2000). More recently, TMPRSS2
has been shown to activate PAR2 but not PAR1 in LNCaP
cells causing Ca2q mobilisation (Wilson et al., 2005). In
addition, the secreted proteinase trypsin IV is able to
cleave peptides representing the activation sequence of
PAR1, PAR2 and PAR4, and, in intact cells, to activate the
corresponding receptors inducing prompt Ca2q mobili-
sation (Knecht et al., 2007). Consistently, treatment of
PC-3 cells with trypsin IV caused calcium ion mobilisa-
tion, presumably through PAR1 and PAR2, as PC-3 cells
lack PAR4 (Cottrell et al., 2004). Potentially, these data
indicate that, as trypsinogen I, II and IV and the endo-
genous activator enteropeptidase are expressed by pros-
tate cancer derived cell lines and tissues, an enzymatic
cascade that mirrors that seen for pancreatic tryptic pro-
teinases in the gastro-intestinal tract may also regulate
PAR signalling in normal and diseased prostate. Such a
cascade may induce activation of an individual PAR or
synergistic activation of multiple members of this recep-
tor family. It is also possible that other membrane bound
and secreted trypsin-like proteinases (and other protein-
ases) will interact similarly to mediate regulation of PAR
signalling.
Cancer-associated consequences of PAR
activation in prostate-derived cell lines
Activation of PARs in prostate cancer cell lines initiates a
variety of cellular processes that are associated with
cancer progression including proliferation, secretion of
tumour promoting factors, changes in morphology and
increased migration (Arora et al., 2007). As indicated
below most of these studies have employed peptides
mimicking PAR tethered ligand sequences to induce sig-
nalling via PARs. In addition, several studies, recognising
the role of thrombin as the endogenous activator of PAR1
and PAR4 in the vasculature (Vu et al., 1991; Xu et al.,
1998), the correlation between hyperactivation of the
coagulation system and tumour progression (Rickles et
al., 1992) and the access of thrombin to cancer cells dur-
ing cancer progression (Trikha and Nakada, 2002), have
also employed this proteinase in studies of the conse-
quences of PAR activation in prostate-derived cells.
A critical component of metastasis is the ability of cells
to migrate/invade, undergo morphological changes and
adhere (Hanahan and Weinberg, 2000). In this respect,
thrombin as well as trypsin stimulated LNCaP migration
towards foetal calf serum in a dose-dependent manner.
The observed proteinase induced migration was mim-
icked by PAR1 and PAR2 activating peptide (AP), but not
by PAR4 AP, signifying the importance of PAR1 and PAR2
in prostate cancer cell migration (Greenberg et al., 2003).
Additionally, a low concentration of thrombin stimulated
PC-3 and DU145 cell migration towards fibronectin (Shi
et al., 2004). Interestingly, higher concentrations of
thrombin resulted in unchanged cell migration of PC-3
cells on fibronectin and significantly decreased cell
migration on plastic, collagen I and IV and laminin
(Loberg et al., 2007), while synergistic treatment with
PAR1 and PAR2 APs enhanced migration similar to throm-
bin in these cell lines. Interestingly, PAR1 AP alone stim-
ulated no migration, while PAR2 AP resulted in only
marginal migration. Thrombin in this study was implicat-
ed as an indirect activator of PAR2, with desensitisation
experiments pre-treating M24met cells with PAR2 agonist
abolishing the effect of thrombin induced migration. Fur-
thermore, experiments employing a PAR2 cleavage
blocking antibody demonstrated that thrombin mediated
effects were cleavage independent (Shi et al., 2004). One
explanation is that PAR1 and PAR2 are forming hetero-
dimers at the cell surface with thrombin mediated chang-
es via PAR1 requiring the interaction of these receptors
(Shi et al., 2004).
The study by Greenberg and co-workers also indicated
the ability of thrombin and trypsin to induce changes in
the morphology of LNCaP cells. Proteolytic treatment
induced cytoskeletal reorganisation after 8 h, and, after
48 h, the projection of filapodia containing actin filaments
and the development of punctate focal adhesions con-
nected with stress fibres consisting of thick actin bundles
(Greenberg et al., 2003). Consistently, PAR1 and PAR2
APs were able to initiate activation of the cytoskeleton
reorganising GTPases RhoA, Rac1 and Cdc42 (Hall,
2005) in a manner similar to thrombin and trypsin in
LNCaP cells (Greenberg et al., 2003). Loberg and col-
leagues have also shown that thrombin treatment of
PC-3 cells causes retraction of the actin cytoskeleton
and numerous microspike extensions from the cell body
(Loberg et al., 2007). This treatment was accompanied
by rapid activation of RhoA and Cdc42 with no change
in the level of Rac-1 activation (Loberg et al., 2007).
Thrombin has also been reported to promote adhesion
of prostate cancer cells to extracellular matrix proteins.
For example, Liu and colleagues have shown that throm-
bin increases DU145 adhesion to fibronectin and laminin
via a mechanism involving PAR1 (Liu et al., 2004). In con-
trast to DU145 cells, treatment of PC-3 cells with a sim-
ilar concentration of thrombin and PAR1 AP decreased
cell adhesion to collagen I and IV and laminin and result-
ed in no change in adhesion to fibronectin (Loberg et al.,
2007). In addition to cell migration and adhesion, exam-
ples of the co-opting of other normal cellular processes
essential for cancer progression, such as tissue remod-
elling, cell growth, angiogenesis and mechanisms regu-
lating apoptosis, have recently been shown to be
mediated via PARs. For example, Wilson and colleagues
have demonstrated that activation of PAR2, but not PAR1,
in LNCaP cells induced increased activity of the tissue
remodelling enzyme matrix metalloproteinase (MMP)-2.
In addition, these workers demonstrated that activation
of both PAR1 and PAR2 induced increased MMP-2 activ-
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ity in PC-3 and DU145 cells, while PAR2 activation
stimulated the activity of another matrix remodelling pro-
teinase, MMP9, in PC-3 cells (Wilson et al., 2004). The
importance of PAR1 for prostate tumour growth in vivo
has also recently been reported. Yin and co-workers
demonstrated that rat Dunning prostate carcinoma cells
expressing human PAR1 displayed a 3.7-fold increase in
tumour mass above controls when grown subcutaneous-
ly in rats (Yin et al., 2003). In addition, low concentrations
of thrombin have been reported to modulate proliferation
of DU145, LNCaP and PNT1A cells (Liu et al., 2003). In
another study, high concentrations of thrombin, acting
through PAR1, impaired the proliferation of DU145 cells
by a mechanism proposed to involve the induction of
apoptosis (Zain et al., 2000). In contrast, pre-treatment
of DU145 and PC-3 cells with thrombin or PAR1 AP pro-
vided a protective effect against docetaxel-induced
apoptosis by mediating increased expression of the anti-
apoptotic protein Bcl-xL (Tantivejkul et al., 2005). Also of
interest, thrombin treatment of DU145 cells has been
shown to induce, via PAR1 activation, elevated secretion
of two cytokines that are implicated in tumour cell
growth, IL-8 and VEGF (Liu et al., 2006). This study is
consistent with a previous report showing that thrombin
stimulation mediated increased VEGF mRNA levels in
PC-3 cells (Huang et al., 2001).
Dysregulated tryptic proteolytic activity
An essential step in aberrant signalling initiated by tryp-
sin-like serine proteinases is dysregulation of proteolytic
activity. This dysregulation requires, quite separate from
increased proteinase expression, the loss of mechanisms
regulating normal activation and cessation of proteolytic
activity. In prostate cancer, as in other diseases, this dys-
regulation is mediated by changes in levels of various
factors including metal ions (e.g., Zn2q) and protein-
aceous inhibitors. For example, in prostate and other tis-
sues, Zn2q ions provide an effective means of regulating
the action of several KLK and other trypsin-like enzymes
including KLK2 (Lovgren et al., 1999a), KLK4 (Debela et
al., 2006a), KLK5 (Michael et al., 2006; Debela et al.,
2007), KLK8 (Kishi et al., 2006), KLK12 (Memari et al.,
2007a) and KLK14 (Borgono et al., 2007c), as well as
prostasin (Shipway et al., 2004) and uPA (Ishii et al.,
2001). Of relevance to normal prostate physiology as well
as prostate cancer, Zn2q levels are up to 10-fold higher
in normal prostate than in other tissues (Kavanagh,
1985), while there is a 10- to 20-fold decrease in these
levels in patients with advanced prostate cancer (Zai-
chick et al., 1996, 1997). Based on in vitro studies this
reduction in Zn2q levels would be expected to be accom-
panied by a corresponding increase in the activity of tryp-
tic proteinases.
Progression of prostate cancer is also often accom-
panied by loss of expression of proteinaceous inhibitors
of trypsin-like enzymes. For example, the serpin anti-
thrombin III which complexes with KLK2 (Cao et al.,
2002) KLK4 (Obiezu et al., 2006), KLK6 (Magklara et al.,
2003), KLK12 (Memari et al., 2007b) and KLK14 (Borgono
et al., 2007c) is down-regulated during prostate cancer
progression (Frenette et al., 1997; Cao et al., 2002). Also,
protein C inhibitor, another serpin which complexes with
KLK1 (Ecke et al., 1992; Espana et al., 1995), KLK2
(Deperthes et al., 1995; Heeb and Espana, 1998; Lovgren
et al., 1999a; Mikolajczyk et al., 1999), KLK5 (Luo and
Jiang, 2006), KLK8 (Luo and Jiang, 2006), KLK12 (Luo
and Jiang, 2006; Memari et al., 2007b) and KLK14 (Luo
and Jiang, 2006), is down-regulated in prostate cancer
(Cao et al., 2003). Further, levels of a-2 macroglobulin,
which forms complexes with KLK2 (Frenette et al., 1997;
Grauer et al., 1998; Heeb and Espana, 1998; Mikolajczyk
et al., 1998), KLK4 (Obiezu et al., 2006), KLK5 (Michael
et al., 2005) and KLK13 (Kapadia et al., 2004), also
decrease during prostate cancer progression (Kanoh et
al., 2001). In addition, as noted above, increased expres-
sion of the TTSP matriptase/MT-SP1 in prostate cancer
is accompanied by decreased expression of the specific
inhibitor of this enzyme (Saleem et al., 2006). Interesting-
ly, in addition to reduced levels of expression of protein-
ase inhibitors during prostate cancer progression there is
evidence that certain trypsin-like serine proteinases also
modulate inhibitor levels by inactivation. For example,
KLK2 has been reported to inactivate the serpin plas-
minogen activator inhibitor-1 by direct cleavage of the
inhibitor (Mikolajczyk et al., 1999). Trypsin IV has also
been reported to deactivate proteinase inhibitors includ-
ing kunitz and kazal type inhibitors and also is generally
resistant to inhibition mediated by proteinaceous inhibi-
tors (Rinderknecht et al., 1984; Nyaruhucha et al., 1997;
Szmola et al., 2003; Salameh et al., 2008).
Conclusion
Many serine proteinases with trypsin-like substrate spec-
ificity are expressed in normal and diseased prostate and
several of these have been shown to regulate intracellular
signalling via PARs. Studies on prostate-derived cell
lines, largely employing activating peptides, the blood
coagulation enzyme, thrombin, and the food digestion
proteinase trypsin, have indicated cancer associated
consequences of PAR activation. In addition, several
reports indicate that cascades involving KLKs and other
serine proteinases will be important for prostatic regula-
tion of PARs. For example, recently Yoon and colleagues,
exploring the ability of 12 members of the KLK family to
process the pro-peptide sequences of all 15 members of
this enzyme family, have demonstrated a number of sig-
nificant cross-activation and autolytic relationships (Yoon
et al., 2007). In addition, the ability of the membrane
anchored serine proteinase enteropeptidase to activate
trypsinogen to trypsin (Yamashina, 1956), the well known
PAR signalling proteinase (Bohm et al., 1996b), may be
a model for the interaction of other secreted and
membrane bound serine proteinases, localising proteo-
lytic activity at the cell surface in close proximity to PARs.
Furthermore, the observation that MMP1 can promote
cell migration and invasion through PAR1 (Boire et al.,
2005) indicates that proteinases from multiple enzyme
families can signal via PARs raising the possibility that
interactions between these proteinase families will be
important in PAR-mediated signalling in physiology and
disease. Also, it is clear that loss of the normal inhibitory
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mechanisms regulating the action of activated trypsin-
like proteinases, such as reduced levels of Zn2q ions and
serpins, have the capacity to contribute significantly to
progression of prostate cancer and other cancers. Finally,
as tryptic proteinases and PARs are widely expressed it
is also likely that interactions between these proteins will
be important in many diseases in addition to prostate
cancer.
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